글로벌 골관절염 치료 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안 골관절염 치료 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 세계보건기구에 따르면 60세 이상의 모든 사람의 약 10%~15%가 골관절염을 앓고 있으며, 여성이 남성보다 유병률이 높습니다. 유엔에 따르면 2050년까지 60세 이상의 성인이 전 세계 인구의 20% 이상을 차지할 것입니다. 이 20% 중 15%는 증상이 있는 골관절염을 앓을 것으로 보수적으로 추정되며, 이 그룹의 3분의 1은 심각하게 고통받을 것입니다.

Data Bridge Market Research는 골관절염 치료 시장이 2021년에 6,214.06백만 달러 규모였으며 2029년까지 10,100.30백만 달러에 도달할 것으로 예상되며 2022년에서 2029년까지의 예측 기간 동안 6.26%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

시장 정의

관절에 영향을 미치는 가장 흔한 만성 질환은 골관절염으로, 종종 퇴행성 관절염이라고도 합니다. 영향을 받는 신체 부위는 이로 인해 급성 관절 통증과 경직을 경험합니다. 골관절염은 관절 통증 완화를 위한 운동과 진통제를 포함한 다양한 방법으로 치료할 수 있습니다. OA 증상은 아세트아미노펜(타이레놀)이나 비스테로이드성 항염제(NSAID)와 같은 일반 의약품(OTC) 진통제로 완화할 수 있습니다. 둘록세틴(심발타)은 처방 진통제로, 장기(만성) OA 불편함을 치료하는 데에도 사용할 수 있습니다. 스테로이드 주사는 종종 단기에서 중기적으로 OA 통증을 상당히 완화할 수 있습니다.

골관절염 치료 시장 동향

운전자

• 골관절염 유병률 증가

골관절염의 유병률 증가는 골관절염 치료 시장의 성장을 촉진할 것으로 추정됩니다. 부상, 비만 및 기타 다양한 요인이 골관절염에 기여합니다. 손상된 신체 부위는 심각한 관절 통증과 경직을 겪습니다. 관절 부기, 다리와 사지의 따끔거림, 운동 범위 감소는 모두 골관절염의 징후입니다. 2020년 11월 Lancet Journal에 발표된 연구에 따르면, 골관절염은 2019년에 전 세계 인구의 약 7%, 즉 5억 명 이상에게 영향을 미쳤으며 여성이 불균형적으로 영향을 받았습니다. 전 세계적으로 골관절염에 걸린 사람의 수는 1990년에서 2019년 사이에 48% 증가했으며, 골관절염은 2019년에 장애 연수(YLD)의 15번째 주요 원인이었습니다.

• 의료 인프라에 대한 투자 증가

Another significant factor influencing the growth rate of osteoarthritis treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to getting osteoarthritis treatment, further estimated to enhance theirmarket's growth rate.

• Surging cases of joint injuries

The increasing number of joint injuries is estimated to elevate the 'market's growth rate. Osteoarthritis can be worsened by injuries sustained while participating in sports or as a result of an accident. Osteoarthritis can be triggered by injuries that occurred many years ago but appear to have healed.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the osteoarthritis treatment market. Additionally, rising incidences of orthopedic disorders and sedentary lifestyle of people will expand the osteoarthritis treatment market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities of medication for symptomatic treatment of osteoarthritis. This will provide beneficial opportunities for the osteoarthritis treatment market growth. For illustration, Flexion Therapeutics, Inc. began a Phase III investigation of FX006 32 mg, which is indicated for knee osteoarthritis, in April 2018.

Moreover, rising investment in the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the osteoarthritis treatment market growth during the forecast period.

Restraints/Challenges

• Side effects linked with Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

NSAIDs, both over-the-counter and prescribed, are commonly used to treat osteoarthritis pain. According to a report published by the National Center for Biotechnology Information in 2019, NSAIDs are administered to more than half of all osteoarthritis patients in the United States. Similarly, 60 percent of osteoarthritis patients in Europe who used prescription drugs (47 percent) received NSAIDs. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been linked to an enhanced risk of cardiovascular events. Both selective and non-selective NSAIDs (coxibs) increase the risk of cardiovascular disease in patients. These factors will impede the 'market's growth rate during the forecast period of 2021-2029.

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the osteoarthritis treatment market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This osteoarthritis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteoarthritis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

X-rays reveal osteoarthritis in about 80% of elderly persons aged 55 and more. Approximately 60% of these people suffer from symptoms. Symptomatic osteoarthritis affects an estimated 240 million adults globally, including over 30 million adults in the United States. Knee osteoarthritis occurs more frequently in postmenopausal women than in males.

Osteoarthritis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Osteoarthritis Treatment Market

Over the projected period, the osteoarthritis treatment market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing many people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The osteoarthritis treatment market was hampered by the supply chain slowness.

Recent Development

• In December 2020, Moebius Medical had announced the US Food and Drug Administration (FDA) clearance for its investigational new drug (IND) application for initiating a global multi-center Phase IIb clinical trial of MM-II, which is a novel candidate for the treatment of pain due to knee osteoarthritis (OA).

Global Osteoarthritis Treatment Market Scope

The osteoarthritis treatment market is segmented on the basis of anatomy, drug type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Anatomy

• Hand Osteoarthritis
• Knee Osteoarthritis
• Hip Osteoarthritis
• Small Joint Osteoarthritis

Drug Type

• Prescription Drugs
• Over-the-Counter Drugs

Treatment Type

• Medication
• Duloxetine
• Acetaminophen
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Others
• Surgery
• Joint Replacement
• Realigning Bones
• Lubrication Injections
• Cortisone Injections
• Therapy
• Transcutaneous Electrical Nerve Stimulation (TENS)
• Occupational Therapy
• Physical Therapy

Diagnosis

• Imaging Tests
• Magnetic resonance imaging (MRI)
• X-rays
• Joint Fluid Analysis
• Blood Tests
• Others

Dosage form

• Tablets
• Injections
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Osteoarthritis Treatment Market Regional Analysis/Insights

The osteoarthritis treatment market is analysed and market size insights and trends are provided by country, anatomy, drug type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the osteoarthritis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the osteoarthritis treatment market because of the launch of new treatment options in this region. Additionally, rising healthcare expenditure along with the availability of treatment options will further propel the 'market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to presence of generic manufacturers in this region. Also, development of healthcare infrastructure and rising geriatric population will further propel the 'market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Osteoarthritis Treatment Market Share Analysis

The Osteoarthritis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteoarthritis treatment market.

Some of the major players operating in the osteoarthritis treatment market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France), Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• Boehringer Ingelheim International GmbH. (Germany)
• Apotex Inc. (Canada)
• AstraZeneca (U.K.)
• Horizon Therapeutics PLC (Ireland)
• Johnson & Johnson Private Limited (U.S.)
• Bayer AG (Germany)
• Perrigo Company plc (Ireland)
• Tolmar Pharmaceuticals, Inc. (U.S.)
• Reckitt Benckiser Group PLC (U.K.)
• Sun Pharmaceutical Industries Ltd. (인도)
• Assertio Therapeutics, Inc.(미국)
• 다이이치 산쿄 주식회사(일본)

SKU-53320